Significant progress has been made in developing novel agents for clinical translational trials; each of these trials has benefited from rapid accrual due to multi-institutional participation among DF/HCC members, along with the use of Cores such as Biostatistics, Cancer Pharmacology, Cancer Proteomics, Cell Manipulation, Cytogenetics, Health Communication, High-Throughput Polymorphism, Rapid Case Identification, Survey and Measurement, and Specialized Histopathology Services.
These trials are each built on preclinical platforms developed within the inter-institutional context of DF/HCC, clearly showing the ability of the DF/HCC infrastructure to facilitate interaction among investigators at disparate sites.
These trials include:
During the period January 1, 2000, through December 31, 2004, 1437 subjects were registered to 67 protocols open for the Gynecologic Cancer Program. Of these protocols, 51 were intervention studies with 701 registrations.
An analysis of accrual patterns by Cancer Center site was performed. Of the Phase 1 and 2 studies that accrued 10 or more subjects (excluding Pediatric, Proton Beam and Cooperative Group Studies), 90% of eligible protocols in this disease program were multi-institutional in accrual by these criteria.
The list of protocols includes 61 non-industry-initiated trials open for this program. These protocols account for 91% of all clinical trials in the Gynecologic Cancers Program and account for 1,356 (94%) of all subject accrual.